Faron Reports Encouraging First Overall Survival Data for Bexmarilimab in Frontline HR-MDS, Median OS Not Yet Reached in Key Subgroups
核心洞察
After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR-MDS patients without TP53 (搜索) mutations or with monoallelic TP53 mutations.
Patients with biallelic TP53 (搜索) mutations achieved a median OS of 8.8 months, consistent with historical outcomes in this highly aggressive population.
The BEXMAB trial evaluates bexmarilimab, an anti-Clever-1 (搜索) immunotherapy, combined with azacitidine in treatment-naïve higher-risk MDS patients.
Faron Pharmaceuticals (搜索) Ltd. has announced the first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (搜索) (HR-MDS) patients enrolled in its BEXMAB trial, revealing that median OS has not yet been reached in two of three key molecular subgroups after a median follow-up of 14.9 months. The data, reported on July 27, 2026, provide an early signal of potential clinical benefit for bexmarilimab, the company's investigational anti-Clever-1 (搜索) immunotherapy, in combination with standard-of-care azacitidine.
The BEXMAB trial is an open-label Phase 1/2 study evaluating bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndromes. Among the 21 treatment-naïve HR-MDS patients enrolled, 48% harbored TP53 (搜索) mutations, a well-established adverse prognostic factor associated with inferior survival outcomes. Of those TP53-mutated patients with known allele frequency data, 33% had monoallelic TP53 alterations and 67% had biallelic TP53 alterations.
Survival Outcomes by TP53 (搜索) Status
At the data cut, the only subgroup to have reached median OS was the biallelic TP53 (搜索) mutated population, which achieved a median OS of 8.8 months. This result is in line with historical data for this particularly aggressive patient population and was described by the company as reassuring given the complex cytogenetics within the BEXMAB biallelic patient cohort.
For patients without TP53 (搜索) mutations (wildtype) and those with monoallelic TP53 mutations, median OS had not yet been reached, indicating that a meaningful proportion of patients in these subgroups remain alive and under follow-up. Survival follow-up is ongoing, and Faron noted that several patients continue to be monitored, providing the opportunity for further maturation of the dataset over time.
"These results further support the potential of bexmarilimab in frontline TP53 (搜索) wild-type and mutated HR-MDS patients, where significant unmet medical need remains," said Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals (搜索). "The data provide additional support as we continue preparations for BEXERA, our planned randomized study evaluating bexmarilimab in combination with azacitidine in frontline HR-MDS patients."
Mechanism of Action and Next Steps
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments by targeting myeloid cell function. The antibody binds to Clever-1 (搜索), an immunosuppressive receptor found on macrophages that contributes to tumor growth and immune evasion. By targeting Clever-1, bexmarilimab reprograms macrophages from an immunosuppressive M2 state to an immunostimulatory M1 state, upregulating interferon production and priming the immune system to attack tumors while sensitizing cancer cells to standard-of-care therapies.
Faron confirmed that the detailed full BEXMAB dataset will be presented at an upcoming scientific meeting later this year. The company is also advancing preparations for BEXERA, a planned randomized study that will further evaluate bexmarilimab in combination with azacitidine in frontline HR-MDS patients.